Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K.

Blood Cancer J. 2015 May 1;5:e309. doi: 10.1038/bcj.2015.30.

2.

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K.

Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.

PMID:
25686603
3.

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples.

He L, Wennerberg K, Aittokallio T, Tang J.

Bioinformatics. 2015 Jun 1;31(11):1866-8. doi: 10.1093/bioinformatics/btv067. Epub 2015 Jan 31.

4.

Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening.

Vidugiriene J, Leippe D, Sobol M, Vidugiris G, Zhou W, Meisenheimer P, Gautam P, Wennerberg K, Cali JJ.

Assay Drug Dev Technol. 2014 Nov-Dec;12(9-10):514-26. doi: 10.1089/adt.2014.605.

5.

Discovery of MINC1, a GTPase-activating protein small molecule inhibitor, targeting MgcRacGAP.

van Adrichem AJ, Fagerholm A, Turunen L, Lehto A, Saarela J, Koskinen A, Repasky GA, Wennerberg K.

Comb Chem High Throughput Screen. 2015;18(1):3-17.

6.

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis.

Khan SA, Virtanen S, Kallioniemi OP, Wennerberg K, Poso A, Kaski S.

Bioinformatics. 2014 Sep 1;30(17):i497-504. doi: 10.1093/bioinformatics/btu456.

7.

Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization.

Ammad-ud-din M, Georgii E, Gönen M, Laitinen T, Kallioniemi O, Wennerberg K, Poso A, Kaski S.

J Chem Inf Model. 2014 Aug 25;54(8):2347-59. doi: 10.1021/ci500152b. Epub 2014 Aug 6.

PMID:
25046554
8.

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T.

Sci Rep. 2014 Jun 5;4:5193. doi: 10.1038/srep05193.

9.

A community effort to assess and improve drug sensitivity prediction algorithms.

Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G.

Nat Biotechnol. 2014 Dec;32(12):1202-12. doi: 10.1038/nbt.2877. Epub 2014 Jun 1.

PMID:
24880487
10.

The high throughput biomedicine unit at the institute for molecular medicine Finland: high throughput screening meets precision medicine.

Pietiainen V, Saarela J, von Schantz C, Turunen L, Ostling P, Wennerberg K.

Comb Chem High Throughput Screen. 2014 May;17(4):377-86.

PMID:
24661208
11.

Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis.

Tang J, Szwajda A, Shakyawar S, Xu T, Hintsanen P, Wennerberg K, Aittokallio T.

J Chem Inf Model. 2014 Mar 24;54(3):735-43. doi: 10.1021/ci400709d. Epub 2014 Feb 21.

PMID:
24521231
12.

Global Human-Kinase Screening Identifies Therapeutic Host Targets against Influenza.

Atkins C, Evans CW, Nordin B, Patricelli MP, Reynolds R, Wennerberg K, Noah JW.

J Biomol Screen. 2014 Jan 24;19(6):936-946. [Epub ahead of print]

PMID:
24464431
13.

Antifungal application of nonantifungal drugs.

Stylianou M, Kulesskiy E, Lopes JP, Granlund M, Wennerberg K, Urban CF.

Antimicrob Agents Chemother. 2014;58(2):1055-62. doi: 10.1128/AAC.01087-13. Epub 2013 Nov 25.

14.

Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells.

Antila H, Autio H, Turunen L, Harju K, Tammela P, Wennerberg K, Yli-Kauhaluoma J, Huttunen HJ, Castrén E, Rantamäki T.

J Neurosci Methods. 2014 Jan 30;222:142-6. doi: 10.1016/j.jneumeth.2013.11.001. Epub 2013 Nov 12.

PMID:
24239780
15.

Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.

Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, Aittokallio T.

PLoS Comput Biol. 2013;9(9):e1003226. doi: 10.1371/journal.pcbi.1003226. Epub 2013 Sep 12.

16.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20.

17.

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.

Rajala HL, Eldfors S, Kuusanmäki H, van Adrichem AJ, Olson T, Lagström S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D, Awwad A, Ellonen P, Kallioniemi O, Wennerberg K, Porkka K, Maciejewski JP, Loughran TP Jr, Heckman C, Mustjoki S.

Blood. 2013 May 30;121(22):4541-50. doi: 10.1182/blood-2012-12-474577. Epub 2013 Apr 17.

18.

A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis.

Wolfe LM, Veeraraghavan U, Idicula-Thomas S, Schürer S, Wennerberg K, Reynolds R, Besra GS, Dobos KM.

Mol Cell Proteomics. 2013 Jun;12(6):1644-60. doi: 10.1074/mcp.M112.025635. Epub 2013 Mar 5.

19.

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs.

Khan SA, Faisal A, Mpindi JP, Parkkinen JA, Kalliokoski T, Poso A, Kallioniemi OP, Wennerberg K, Kaski S.

BMC Bioinformatics. 2012 May 30;13:112. doi: 10.1186/1471-2105-13-112.

20.

Somatic STAT3 mutations in large granular lymphocytic leukemia.

Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S.

N Engl J Med. 2012 May 17;366(20):1905-13. doi: 10.1056/NEJMoa1114885.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk